Latest Articles
BioGrad opens Europe’s first private research tissue bank as part of a £25m investment into women’s health - Growth Platform
BioGrad opens Europe’s first private research tissue bank as part of a £25m investment into women’s health Growth Platform
Published: Jan. 21, 2025, 2:16 p.m.
Endometriosis Treatment Drugs Market Expected to Hit USD 16.6 Billion by 2032 with a Remarkable 4.91% CAGR - EIN News
Endometriosis Treatment Drugs Market Expected to Hit USD 16.6 Billion by 2032 with a Remarkable 4.91% CAGR EIN News
Published: Jan. 21, 2025, 10:38 a.m.
BioGrad opens Europe’s first private research tissue bank as part of a £25m investment into women’s health - Invest Liverpool
BioGrad opens Europe’s first private research tissue bank as part of a £25m investment into women’s health Invest Liverpool
Published: Jan. 21, 2025, 9:51 a.m.
Endometriosis Treatment Drugs Market Expected to Hit USD 16.6 Billion by 2032 with a Remarkable 4.91% CAGR - ABN Newswire
Endometriosis Treatment Drugs Market Expected to Hit USD 16.6 Billion by 2032 with a Remarkable 4.91% CAGR ABN Newswire
Published: Jan. 21, 2025, 12:38 a.m.
Neutrophils initiate pro-inflammatory immune responses in early endometriosis lesion development.
Endometriosis is a chronic gynecological disease that affects 1 in 10 reproductive-aged women. Most studies investigate established disease; however, the initiation and early events in endometriotic lesion development remain poorly …
Published: Jan. 21, 2025, midnight
Management of Diaphragmatic Central Tendon Plays an Important Role in the Surgical Treatment of Catamenial Pneumothorax: A Case Report - Cureus
Management of Diaphragmatic Central Tendon Plays an Important Role in the Surgical Treatment of Catamenial Pneumothorax: A Case Report Cureus
Published: Jan. 20, 2025, 9:41 p.m.
Gesynta Pharma Raises $29M to Advance Non-Hormonal Endometriosis Treatment - Femtech Insider
Gesynta Pharma Raises $29M to Advance Non-Hormonal Endometriosis Treatment Femtech Insider
Published: Jan. 20, 2025, 10:56 a.m.
Gesynta Pharma Raises SEK 304 Million to Advance Novel Endometriosis Treatment - beQuoted
Gesynta Pharma Raises SEK 304 Million to Advance Novel Endometriosis Treatment beQuoted
Published: Jan. 20, 2025, 8:21 a.m.
GSK’s Jemperli gains EU approval for advanced endometrial cancer treatment - DirectorsTalk Interviews
GSK’s Jemperli gains EU approval for advanced endometrial cancer treatment DirectorsTalk Interviews
Published: Jan. 20, 2025, 7:28 a.m.
GSK’s Jemperli Gains Expanded EU Approval for Broader Endometrial Cancer Treatment - TipRanks
GSK’s Jemperli Gains Expanded EU Approval for Broader Endometrial Cancer Treatment TipRanks
Published: Jan. 20, 2025, 7:19 a.m.
Link copied to clipboard!